Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCT 200

Drug Profile

SCT 200

Alternative Names: Recombinant anti-EGFR monoclonal antibody - Sinocelltech; SCT-200

Latest Information Update: 31 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Oesophageal cancer
  • Phase I Colorectal cancer

Most Recent Events

  • 14 Mar 2019 Sinocelltech plans a phase II trial for Head and Neck cancer (Combination therapy, First-line therapy, Recurrent, Metastatic disease) in China in March 2019 (NCT03874741)
  • 17 Jan 2019 Sinocelltech plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in March 2019 (NCT03808701)
  • 16 Nov 2018 Chinese Academy of Medical Sciences plans a phase II trial for Head and Neck cancer (Recurrent, Late-stage disease, First-line therapy) in December 2018 (NCT03744208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top